{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:17:26Z","timestamp":1790266646745,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,2,12]],"date-time":"2019-02-12T00:00:00Z","timestamp":1549929600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13195-019-0467-2","type":"journal-article","created":{"date-parts":[[2019,2,12]],"date-time":"2019-02-12T11:04:15Z","timestamp":1549969455000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer\u2019s disease"],"prefix":"10.1186","volume":"11","author":[{"given":"Lutz","family":"Fr\u00f6lich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glen","family":"Wunderlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Thamer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Roehrle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Miguel","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Dubois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,12]]},"reference":[{"issue":"4","key":"467_CR1","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.jalz.2016.03.001","volume":"12","author":"Alzheimer's Association","year":"2016","unstructured":"Alzheimer's Association. 2016 Alzheimer\u2019s disease facts and figures. Alzheimers Dement. 2016;12(4):459\u2013509.","journal-title":"Alzheimers Dement"},{"issue":"Suppl 1","key":"467_CR2","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1017\/cjn.2016.36","volume":"43","author":"KM Fiest","year":"2016","unstructured":"Fiest KM, et al. The prevalence and incidence of dementia due to Alzheimer\u2019s disease: a systematic review and meta-analysis. Can J Neurol Sci. 2016;43(Suppl 1):S51\u201382.","journal-title":"Can J Neurol Sci"},{"issue":"11","key":"467_CR3","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/S1474-4422(10)70223-4","volume":"9","author":"B Dubois","year":"2010","unstructured":"Dubois B, et al. Revising the definition of Alzheimer\u2019s disease: a new lexicon. Lancet Neurol. 2010;9(11):1118\u201327.","journal-title":"Lancet Neurol"},{"issue":"5","key":"467_CR4","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1159\/000067427","volume":"11","author":"HG Lee","year":"2002","unstructured":"Lee HG, et al. Differential regulation of glutamate receptors in Alzheimer\u2019s disease. Neurosignals. 2002;11(5):282\u201392.","journal-title":"Neurosignals"},{"key":"467_CR5","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/7355_2010_8","volume":"6","author":"KR Bales","year":"2010","unstructured":"Bales KR, et al. Phosphodiesterase inhibition to target the synaptic dysfunction in Alzheimer\u2019s disease. Topics Med Chem. 2010;6:57\u201390.","journal-title":"Topics Med Chem"},{"issue":"1\u20133","key":"467_CR6","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s00213-008-1273-x","volume":"202","author":"OA Reneerkens","year":"2009","unstructured":"Reneerkens OA, et al. Selective phosphodiesterase inhibitors: a promising target for cognition enhancement. Psychopharmacology. 2009;202(1\u20133):419\u201343.","journal-title":"Psychopharmacology"},{"issue":"5","key":"467_CR7","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1111\/bcp.13060","volume":"82","author":"V Moschetti","year":"2016","unstructured":"Moschetti V, et al. First-in-human study assessing safety, tolerability and pharmacokinetics of BI 409306, a selective phosphodiesterase 9A inhibitor, in healthy males. Br J Clin Pharmacol. 2016;82(5):1315\u201324.","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"467_CR8","doi-asserted-by":"publisher","first-page":"641","DOI":"10.2165\/00023210-200317090-00004","volume":"17","author":"DA Butterfield","year":"2003","unstructured":"Butterfield DA, Pocernich CB. The glutamatergic system and Alzheimer\u2019s disease: therapeutic implications. CNS Drugs. 2003;17(9):641\u201352.","journal-title":"CNS Drugs"},{"issue":"5","key":"467_CR9","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.tins.2018.02.001","volume":"41","author":"R Ricciarelli","year":"2018","unstructured":"Ricciarelli R, Fedele E. cAMP, cGMP and amyloid \u03b2: three ideal partners for memory formation. Trends Neurosci. 2018;41(5):255\u201366.","journal-title":"Trends Neurosci"},{"issue":"Suppl 1","key":"467_CR10","first-page":"S36","volume":"41","author":"H Rosenbrock","year":"2015","unstructured":"Rosenbrock H, et al. BI 409306, a novel phosphodiesterase 9A inhibitor, part II: in-vivo characterization regarding target engagement and cognition tasks in rodents. Schizophr Bull. 2015;41(Suppl 1):S36.","journal-title":"Schizophr Bull"},{"issue":"7","key":"467_CR11","doi-asserted-by":"publisher","first-page":"P612","DOI":"10.1016\/j.jalz.2015.06.852","volume":"11","author":"H Rosenbrock","year":"2015","unstructured":"Rosenbrock H, et al. Improving synaptic plasticity and cognitive function in rodents by the novel phosphodiesterase 9A inhibitor BI 409306. Alzheimers Dementia. 2015;11(7):P612 [Abstract].","journal-title":"Alzheimers Dementia"},{"issue":"9, Suppl","key":"467_CR12","first-page":"275S","volume":"77","author":"H Rosenbrock","year":"2015","unstructured":"Rosenbrock H, et al. Pharmacological characterization of the novel phosphodiesterase 9A inhibitor BI 409306 in animal models related to synaptic plasticity and cognitive function. Biol Psychiatry. 2015;77(9, Suppl):275S [Abstract].","journal-title":"Biol Psychiatry"},{"issue":"Suppl 1","key":"467_CR13","first-page":"S31","volume":"41","author":"C Dorner-Ciossek","year":"2015","unstructured":"Dorner-Ciossek C, Giovannini R, Rosenbrock H. BI 409306, a novel phosphodiesterase 9A inhibitor, part I: potency, selectivity and in-vitro functional characterization on synaptic plasticity. Schizophr Bull. 2015;41(Suppl 1):S31.","journal-title":"Schizophr Bull"},{"issue":"6","key":"467_CR14","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","volume":"13","author":"B Dubois","year":"2014","unstructured":"Dubois B, et al. Advancing research diagnostic criteria for Alzheimer\u2019s disease: the IWG-2 criteria. Lancet Neurol. 2014;13(6):614\u201329.","journal-title":"Lancet Neurol"},{"issue":"1","key":"467_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2011.10.007","volume":"8","author":"BT Hyman","year":"2012","unstructured":"Hyman BT, et al. National Institute on Aging\u2013Alzheimer\u2019s Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dementia. 2012;8(1):1\u201313.","journal-title":"Alzheimers Dementia"},{"key":"467_CR16","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use: Guideline for Good Clinical Practice E6 (1). 1996."},{"key":"467_CR17","volume-title":"Declaration of Helsinki - ethical principles for medical research involving human subjects","author":"World Medical Association","year":"2013","unstructured":"World Medical Association Declaration of Helsinki - ethical principles for medical research involving human subjects. 2013."},{"issue":"9","key":"467_CR18","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1001\/archneur.64.9.1323","volume":"64","author":"J Harrison","year":"2007","unstructured":"Harrison J, et al. A neuropsychological test battery for use in Alzheimer disease clinical trials. Arch Neurol. 2007;64(9):1323\u20139.","journal-title":"Arch Neurol"},{"issue":"5","key":"467_CR19","doi-asserted-by":"publisher","first-page":"413","DOI":"10.2174\/1567205011666140505100858","volume":"11","author":"EM Schwam","year":"2014","unstructured":"Schwam EM, et al. A multicenter, double-blind, placebo-controlled trial of the PDE9A inhibitor, PF-04447943, in Alzheimer\u2019s disease. Curr Alzheimer Res. 2014;11(5):413\u201321.","journal-title":"Curr Alzheimer Res"},{"issue":"1","key":"467_CR20","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13195-017-0283-5","volume":"9","author":"PS Aisen","year":"2017","unstructured":"Aisen PS, et al. On the path to 2025: understanding the Alzheimer\u2019s disease continuum. Alzheimers Res Ther. 2017;9(1):60.","journal-title":"Alzheimers Res Ther"},{"issue":"9","key":"467_CR21","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1080\/13543784.2017.1364360","volume":"26","author":"J Prickaerts","year":"2017","unstructured":"Prickaerts J, Heckman PRA, Blokland A. Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzheimer\u2019s disease. Expert Opin Investig Drugs. 2017;26(9):1033\u201348.","journal-title":"Expert Opin Investig Drugs"},{"issue":"4","key":"467_CR22","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1080\/09540260802094548","volume":"20","author":"JL Cummings","year":"2008","unstructured":"Cummings JL. Controversies in Alzheimer\u2019s disease drug development. Int Rev Psychiatry. 2008;20(4):389\u201395.","journal-title":"Int Rev Psychiatry"}],"container-title":["Alzheimer's Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-019-0467-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13195-019-0467-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-019-0467-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T20:36:57Z","timestamp":1581971817000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-019-0467-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,12]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["467"],"URL":"https:\/\/doi.org\/10.1186\/s13195-019-0467-2","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,12]]},"assertion":[{"value":"25 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Both studies were approved by their respective institutional review board\/independent ethics committee and the competent authorities as per national and international regulations (Study 1: Medizinische Ethikkommission II der Medizinischen Fakult\u00e4t Mannhein, Germany; Study 2: CPP Ile -de-France X, H\u00f4pital Robert Ballanger, France), and conducted in accordance with the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Guideline for Good Clinical Practice and local legislation, as per the principles of the Declaration of Helsinki [, ].","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"LF has previously received grants from Novartis, Piramal, Merz Pharma GmbH and Janssen-Cilag GmbH and has also received personal fees from AstraZeneca, Avraham Pharma, Axon Neuroscience, Baxter, Biogen, Boehringer Ingelheim, Eisai, Eli Lilly & Co, GE Healthcare, Janssen-Cilag, Lundbeck A\/S, Merck Sharp and Dohme, Novartis, Nutricia, Pfizer, Pharnext, PharmatrophiX, Piramal, Schering-Plough and Takeda. CT and MR are employees of Boehringer Ingelheim International GmbH. GW is an employee of Boehringer Ingelheim Canada Ltd. MG is an employee of Boehringer Ingelheim Pharmaceuticals Inc. BD has participated in advisory boards for Axovant, Biogen, Boehringer Ingelheim International and Lilly and has previously received grants from Merck, Pfizer and Roche.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"18"}}